Nicholas Tulshi
Family · Opelika, ALNPI 1598380016
Payments from drug & device makers
Across 223 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$782
- Novo Nordisk$615
- Lilly USA, LLC$365
- AstraZeneca$335
- Takeda Pharmaceuticals U.S.A., Inc.$216
- Pfizer$171
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $782 |
| Novo Nordisk | 35 | $615 |
| Lilly USA, LLC | 29 | $365 |
| AstraZeneca | 16 | $335 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $216 |
| Pfizer | 11 | $171 |
| GSK | 8 | $161 |
| Eisai Inc. | 6 | $131 |
| Boehringer Ingelheim | 8 | $112 |
| Exact Sciences | 7 | $111 |
| Astellas Pharma US Inc | 6 | $95 |
| Merck | 6 | $79 |
| Amgen | 4 | $77 |
| Novartis | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$3,733 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $128,134 |
| EliquisApixaban | 80 | $83,567 |
| FarxigaDapagliflozin Propanediol | 40 | $41,198 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $34,408 |
| TrulicityDulaglutide | 24 | $26,229 |
| JardianceEmpagliflozin | 15 | $22,559 |
| CreonLipase/Protease/Amylase | 29 | $17,041 |
| RybelsusSemaglutide | 16 | $15,201 |
| MyrbetriqMirabegron | 22 | $10,585 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,502 |
| Atorvastatin Calcium | 574 | $8,090 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,597 |
| Repatha SureclickEvolocumab | 13 | $7,105 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $7,027 |
| Omeprazole | 312 | $4,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $615 | $143,335134 claims |
| PfizerEliquis | $171 | $83,56780 claims |
| AstraZenecaFarxiga, Symbicort | $335 | $48,79569 claims |
| GSKTrelegy Ellipta | $161 | $34,40853 claims |
| Lilly USA, LLCTrulicity | $365 | $26,22924 claims |
| Boehringer IngelheimJardiance | $112 | $22,55915 claims |
| AbbVieCreon | $782 | $17,04129 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $10,58522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Opelika
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.